Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLKB1 | P03952 | 20/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.82 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.82 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.82 |
| ▸ | F2 | P00734 | 1/20 | 0.73 |
| ▸ | F11 | P03951 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17785277 | 1.00 | KLKB1 (1.00) | KLKB1CYP3A4CYP2C8CYP2C9F2 | |
| SCHEMBL21145568 | 0.92 | KLKB1 (1.00) | KLKB1CYP3A4CYP2C8CYP2C9F2 | |
| SCHEMBL21145572 | 0.92 | KLKB1 (1.00) | KLKB1CYP3A4CYP2C8CYP2C9F2 | |
| SCHEMBL17785395 | 0.92 | KLKB1 (1.00) | KLKB1CYP3A4CYP2C8CYP2C9F2 | |
| SCHEMBL29835938 | 0.92 | KLKB1 (1.00) | KLKB1CYP3A4CYP2C8CYP2C9F2 | |
| SCHEMBL21145621 | 0.90 | KLKB1 (1.00) | KLKB1CYP3A4CYP2C8CYP2C9F2 | |
| SCHEMBL21145619 | 0.90 | KLKB1 (0.82) | KLKB1CYP3A4CYP2C8CYP2C9F2 | |
| SCHEMBL17785373 | 0.90 | KLKB1 (1.00) | KLKB1CYP3A4CYP2C8CYP2C9F2 | |
| SCHEMBL17785423 | 0.90 | KLKB1 (1.00) | KLKB1CYP3A4CYP2C8CYP2C9F2 | |
| SCHEMBL21120927 | 0.89 | KLKB1 (0.89) | KLKB1CYP3A4CYP2C8CYP2C9F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220289729-A1 | N-((HET)Arylmethyl)-Heteroaryl-Carboxamides Compounds As Kallikrein Inhibitors | KALVISTA PHARMACEUTICALS LTD (GB) | 2022-09-15 | — | — | US | claimed |
| US-20220289729-A1 | N-((HET)Arylmethyl)-Heteroaryl-Carboxamides Compounds As Kallikrein Inhibitors | KALVISTA PHARMACEUTICALS LTD (GB) | 2022-09-15 | — | — | US | disclosed |
| EP-4039681-A1 | N-((HET)ARYLMETHYL)-HETEROARYL-CARBOXAMIDES COMPOUNDS AS PLASMA KALLIKREIN INHIBITORS | Kalvista Pharmaceuticals Limited (GB) | 2022-08-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220289729-A1 | N-((HET)Arylmethyl)-Heteroaryl-Carboxamides Compounds As Kallikrein Inhibitors | KLKB1, BDKRB1, BDKRB2 | KLKB1 1/4885CYP3A4 1261/4885CYP2C8 1116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.